Complement factor I-related compositions and methods

US12116606B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Grant E. BLOUSE · Burlingame, US
• Brajesh KUMAR · Fremont, US
• Tom KNUDSEN · Burlingame, US
• Jan Kristian JENSEN · Randers, DK
• Emil OLDENBURG · Aarhus, DK
• Christine René SCHAR · Randers, DK
• Matthew John Traylor · Boulder, US
• Eric Furfine · Concord, US
• Jeffrey Charles Way · Cambridge, US
• Agnieszka JENDROSZEK · Brendstrup, DK
• Arzu SANDIKCI · Berkeley, US
• Jim McGuire · South San Francisco, US
• Shyam Rajan IYER · Woodside, US
• Natacha Le Moan · San Francisco, US

Key dates

• Filing date: Jun 14, 2021
• Grant date: Oct 15, 2024
• Expiry date: Jun 26, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are Complement Factor I (CFI) variants that exhibit at least one improved characteristic relative to a wild type CFI. CFI variants of the disclosure can exhibit tunable specificity and activity. Also included are CFI-containing fusion constructs comprising at least one domain of CFI, for example, wild type full length CFI fused to human serum albumin. Also included are methods of making and using such CFI variants and fusion constructs. The CFI variants and fusion constructs provided herein may be useful for treating a disease or condition associated with dysregulation of the complement system or a deficiency of CFI.